Endothelial Surface N-Glycans Mediate Monocyte Adhesion and Are Targets for Anti-inflammatory Effects of Peroxisome Proliferator-activated Receptor γ Ligands*

Background: Activation of peroxisome proliferator-activated receptor (PPAR) γ in endothelial cells inhibits tumor necrosis factor (TNF) α-dependent monocyte adhesion. Results: TNFα and PPARγ target endothelial high mannose/hybrid N-glycan expression to regulate monocyte rolling adhesion. Conclusion: High mannose/hybrid N-glycoforms on the endothelial surface mediate monocyte interactions during inflammation. Significance: N-Glycan processing enzymes may be novel targets to control vascular inflammatory processes. Endothelial-monocyte interactions are regulated by adhesion molecules and key in the development of vascular inflammatory disease. Peroxisome proliferator-activated receptor (PPAR) γ activation in endothelial cells is recognized to mediate anti-inflammatory effects that inhibit monocyte rolling and adhesion. Herein, evidence is provided for a novel mechanism for the anti-inflammatory effects of PPARγ ligand action that involves inhibition of proinflammatory cytokine-dependent up-regulation of endothelial N-glycans. TNFα treatment of human umbilical vein endothelial cells increased surface expression of high mannose/hybrid N-glycans. A role for these sugars in mediating THP-1 or primary human monocyte rolling and adhesion was indicated by competition studies in which addition of α-methylmannose, but not α-methylglucose, inhibited monocyte rolling and adhesion during flow, but not under static conditions. This result supports the notion that adhesion molecules provide scaffolds for sugar epitopes to mediate adhesion with cognate receptors. A panel of structurally distinct PPARγ agonists all decreased TNFα-dependent expression of endothelial high mannose/hybrid N-glycans. Using rosiglitazone as a model PPARγ agonist, which decreased TNFα-induced high mannose N-glycan expression, we demonstrate a role for these carbohydrate residues in THP-1 rolling and adhesion that is independent of endothelial surface adhesion molecule expression (ICAM-1 and E-selectin). Data from N-glycan processing gene arrays identified α-mannosidases (MAN1A2 and MAN1C1) as targets for down-regulation by TNFα, which was reversed by rosiglitazone, a result consistent with altered high mannose/hybrid N-glycan epitopes. Taken together we propose a novel anti-inflammatory mechanism of endothelial PPARγ activation that involves targeting protein post-translational modification of adhesion molecules, specifically N-glycosylation.


Endothelial-monocyte interactions are regulated by adhesion molecules and key in the development of vascular inflammatory disease. Peroxisome proliferator-activated receptor (PPAR) ␥ activation in endothelial cells is recognized to mediate anti-inflammatory effects that inhibit monocyte rolling and adhesion. Herein, evidence is provided for a novel mechanism for the antiinflammatory effects of PPAR␥ ligand action that involves inhibition of proinflammatory cytokine-dependent up-regulation of endothelial N-glycans. TNF␣ treatment of human umbilical vein endothelial cells increased surface expression of high mannose/hybrid N-glycans.
A role for these sugars in mediating THP-1 or primary human monocyte rolling and adhesion was indicated by competition studies in which addition of ␣-methylmannose, but not ␣-methylglucose, inhibited monocyte rolling and adhesion during flow, but not under static conditions. This result supports the notion that adhesion molecules provide scaffolds for sugar epitopes to mediate adhesion with cognate receptors. A panel of structurally distinct PPAR␥ agonists all decreased TNF␣-dependent expression of endothelial high mannose/hybrid N-glycans. Using rosiglitazone as a model PPAR␥ agonist, which decreased TNF␣-induced high mannose N-glycan expression, we demonstrate a role for these carbohydrate residues in THP-1 rolling and adhesion that is independent of endothelial surface adhesion molecule expression (ICAM-1 and E-selectin). Data from N-glycan processing gene arrays identified ␣-mannosidases (MAN1A2 and MAN1C1) as targets for down-regulation by TNF␣, which was reversed by rosiglitazone, a result consistent with altered high mannose/hybrid N-glycan epitopes. Taken together we propose a novel antiinflammatory mechanism of endothelial PPAR␥ activation that involves targeting protein post-translational modification of adhesion molecules, specifically N-glycosylation.
Inflammation underlies the pathogenesis of numerous vascular diseases including atherosclerosis (1)(2)(3)(4). A central tenet of this process is increased interactions between circulating leukocytes and the endothelium, which occurs via the sequential steps of rolling, firm adhesion, and ultimately transmigration into the vessel wall (4). Typically, increased leukocyte adhesion to the endothelium comprises an early event that can be stimulated by several factors including proinflammatory cytokines (e.g. tumor necrosis factor ␣ (TNF␣)).
A widely accepted mechanism for increased leukocyte adhesion is the up-regulation of endothelial adhesion molecule expression. However, as discussed previously (5-7), many adhesion molecules are glycosylated (via O-or N-linkages) or sulfated. These post-translational modifications may be important for correct trafficking to the plasma membrane and in many cases are the actual ligands that mediate adhesive interactions with leukocytes. Importantly, incorrect glycosylation can render the adhesion molecule inactive with respect to rolling and/or adhesion of circulating leukocytes. It has been suggested that under basal conditions not all expressed adhesion molecules are functional due to incorrect glycosylation (7). Interestingly, differential expression of glycans on the luminal surface at specific and distinct regions in the vasculature has been associated with different vascular inflammatory diseases, thus the glycan profile is analogous to a molecular zip code that regulates leukocyte trafficking (8).
Although evidence for both O-and N-glycans in mediating inflammatory processes exists, less is known about N-glycans. Some studies have demonstrated the importance of N-glycans in providing endothelial ligands for cognate receptors on neutrophils and lymphocytes (9 -11). However, relatively little is known about how this post-translational modification of adhesion molecules is regulated during inflammation (12) and whether this occurs in a manner that overlaps with, or is dis-tinct from mechanisms that control up-regulation of adhesion molecule protein expression.
Peroxisome proliferator activated receptor ␥ (PPAR␥) 3 is a nuclear receptor/transcription factor, which upon activation by a ligand, binds to PPAR-response elements on target genes resulting in either activation or inhibition of transcription. Transcriptional activity of these complexes is regulated by PPAR ligands. PPAR␥ activation has been investigated largely from the perspective of the regulation of genes that control lipid and glucose metabolism (13)(14)(15), with recent data suggesting critical roles in inhibiting vascular inflammation (15)(16)(17)(18). The anti-inflammatory mechanisms remain poorly defined, and depending on the experimental conditions employed, can be associated with an inhibition of cytokine-dependent expression of endothelial adhesion molecules (16). Our recent studies suggest that PPAR␥ ligand treatment of endothelial cells under static conditions attenuates subsequent TNF␣-dependent monocyte rolling and adhesion. Moreover, this effect is independent of TNF␣-dependent increased adhesion molecule expression (19,20). However, the mechanism for this effect remains unclear. In this study we provide evidence that PPAR␥ activation can prevent monocyte rolling and adhesion to TNF␣-activated endothelial cells by selectively targeting adhesion molecule N-glycosylation. Specifically, we show that (i) TNF␣ stimulates endothelial expression of N-glycans (specifically of the high mannose and/or hybrid type) at cell junctions, (ii) that these epitopes play a role in modulating monocyte rolling and adhesion to the endothelium, and (iii) reveal a novel anti-inflammatory effect of PPAR␥ ligands in inhibiting TNF␣ dependent up-regulation of endothelial surface N-glycans.
Cell Culture and Viability-HUVEC and HAEC were cultured as previously described (20) and used between passages 3 and 7. All experiments were performed within 1 day of cells reaching confluence. THP-1 cells were maintained in RPMI 1640 containing 10% FBS, 1 mg/ml of penicillin-streptomycin at 0.5-1.0 ϫ 10 6 cells/ml to maintain them in the log cell growth phase. For adhesion experiments either under static conditions or flow, monocytes were labeled with Cell Tracker Green (1 M) for 15 min at 37°C in the dark. Cells were washed twice in sterile warm PBS (400 ϫ g for 5 min) to remove unincorporated dye. Cell viability was assessed by trypan blue dye exclusion and was Ͼ95% in all preparations. Endothelial cells were treated with PPAR␥ ligands and TNF-␣ as described below, washed with sterile, warm PBS (2 times), and then used in adhesion assays or processed for lectin fluorescence analysis described below. Due to varying specific activities of TNF␣ from one batch to another, concentrations that increased monocyte adhesion to endothelial cells under static conditions by 2-fold was determined (varied between 2 and 10 ng/ml) and those concentrations were used in this study. Results from either HUVEC or human aortic endothelial cells were similar with respect to the TNF␣-dependent changes in N-glycan profiles and inhibitory effects of rosiglitazone toward monocyte rolling and adhesion.
␣-Mannosidase Activity-␣-Mannosidase activity was determined as described with minor modifications (21). Cells were treated as described and lysed in PBS containing 1% Triton X-100 for 10 min on ice before clarification at 10,000 ϫ g for 10 min. For each reaction, 50 l of lysate (corresponding to 25-40 g of protein) was combined with 10 l of acetate buffer (1 M sodium acetate, pH 6.5) and 40 l of 25 mM p-nitrophenol-␣mannopyranoside in a microtiter plate. Plates were incubated for 2 h at 37°C and the reaction was stopped by the addition of 100 l of stop solution (133 mM glycine, 67 mM NaCl, 83 mM sodium carbonate, pH 10.4) and absorbance was measured at 405 nm. To determine specificity of reaction some samples also included 0.5 mM swainsonine or 0.1 g/l of kifunensine. Activity is reported as the relative absorbance per g of protein.
Each sample was run in duplicate and each treatment condition was tested 4 -6 times.
Static Adhesion Assay-Static adhesion assays were performed as previously described (20). Briefly, HUVEC were grown in 48-well plates and treated with PPAR␥ ligand for 16 h (in all cases PPAR␥ ligand stock concentrations were diluted to ensure identical volumes were added, and where appropriate vehicle controls included) and during the last 4 h coincubated with or without TNF␣. Cells were then washed twice with warm sterile PBS and incubated with monocytes at a final monocyte:endothelial cell ratio of 6:1 for 30 min at 37°C in a 5% CO 2 incubator. The bound and unbound fractions were collected separately and fluorescence was measured using a PerkinElmer fluorescent plate reader (excitation ϭ 485 nm, emission ϭ 535 nm) and the percent of monocytes bound was determined.
In Vitro Flow Assay-Leukocyte rolling and firm adhesion during flow were determined as previously described (19,20) using the Glycotech flow chamber system (Rockville, MD). Briefly, HUVEC were cultured in 35-mm dishes and treated with vehicle or PPAR␥ ligand for 16 h and during the last 4 h coincubated with or without TNF␣. HUVEC were washed twice with warm sterile PBS and THP-1 monocytes labeled with Cell Tracker Green, then flowed over the endothelium at 100 -300 l/min corresponding to a wall shear rate (or shear stress the endothelial cells experience) of 0.5-1.5 dynes/cm 2 in RPMI basal media (without serum) containing calcium and magnesium. The flow system forms a laminar flow on the endothelial cell monolayer. HUVEC and the labeled monocytes were maintained at 37°C throughout the duration of the experiment. The cells were viewed on a Leica inverted fluorescence microscope equipped with a Hamamatsu Orca ER digital CCD camera (Compix, Cranberry Township, PA). Real-time images of each field were captured at 33 frames/s for 2 min, and the resulting time lapse images were analyzed to calculate average rolling velocities. This was performed by motion tracking analysis using the Automated Image Capture and Motion Tracking and Analysis software (Simple PCI, Compix Inc., Cranberry Township, PA). Any cell that did not move for 5 s or more was considered to be firmly bound and numbers were calculated per min of data acquired. For experiments designed to determine the number of rolling monocytes and monocyte rolling velocities, 100,000 cells/ml were used. For experiments determining the number of adhered monocytes during flow, 250,000 cells/ml were used. To distinguish cells rolling on the endothelium via adhesive interactions from those freely flowing in the perfusion buffer close to the endothelium, the critical rolling velocity for THP-1 cells will be calculated as previously described (19,20). Any cell traveling at a velocity below the critical rolling velocity is considered in contact with the endothelium, and as such is able to engage in rolling adhesions.
Sugar Competition Experiments-For sugar inhibition experiments, either ␣-methylglucoside or ␣-methylmannoside (0 -200 mM) were mixed with THP-1 immediately (Ͻ30 s) prior to initiation of flow. In this protocol, the total exposure time of monocytes to sugars before exposure of monocytes to endothelium was Ͻ2 min. Viability of THP-1 exposed to the highest concentration of sugar used for 10 min was Ͼ95% assessed by Trypan blue exclusion (not shown). Note, interactions of monocytes and endothelium were followed for 2 min only (see above) and no changes in endothelial morphology or viability were observed over this period after exposure to the highest concentration of sugar used. Osmolarity of media (measured by vapor pressure osmometry) increased with increasing sugar concentrations, but was not different between mannose and glucose being 298 Ϯ 5 (PBS), 295 Ϯ 3.2 (RPMI), 297 Ϯ 7.8 and 295 Ϯ 0.5 (RPMI ϩ 2 mM glucose and mannose, respectively), 312 Ϯ 1.5 and 310 Ϯ 3 (RPMI ϩ 20 mM glucose and mannose, respectively), and 500 Ϯ 0.7 and 500 Ϯ 3.5 (RPMI ϩ 200 mM glucose and mannose, respectively).
Lectin Staining-HUVECs were grown on microscope coverslips in endothelial basal medium containing 2% FBS. After treatments, cells were washed using ice-cold PBS containing 1 mM each CaCl 2 and MgCl 2 (2 ml, 2 times) and then stained with 10 g/ml of lectin for 15 min on ice. Cells were washed with PBS (2 times) and fixed using 4% paraformaldehyde in PBS for 10 min at room temperature. Fixed cells were washed, DNA was stained with Hoechst 33342 (Molecular Probes), and coverslips were mounted for viewing. For different lectin-fluorescent conjugates, pilot studies were performed to define doses and incubation times for optimal binding. Images were acquired using a Leica fluorescent microscope and confocal images were acquired by the University of Alabama at Birmingham, Center for Developmental and Functional Imaging on a Zeiss LSM 710 confocal microscope. For 96-well plate-based staining, HUVECs were grown to confluence and were stained as above (lectin concentration was lowered to 1 g/well). After fixation, plates were read on a Victor 2 plate reader (PerkinElmer Life Sciences). The different lectins used and their specificities are shown in Table 1.
Immunofluorescent Staining-HUVECs were stained with lectins as above, fixed, permeabilized with 0.1% Triton X-100 for 5 min at room temperature, and then blocked with 5% goat serum in PBS. After blocking, coverslips were incubated with mouse anti-occludin (1:200, Abcam) in PBS containing 5% goat serum overnight at 4°C. Following washing, cells were incubated with goat anti-mouse Alexa Fluor 594 (1:1000, Molecular Probes) in PBS with 5% goat serum for 1 h at RT. DNA were stained with Hoechst 33342, coverslips were mounted, and images were acquired using a Leica fluorescent microscope.
Statistical Analysis-In vitro flow and static adhesion experiments were conducted Ͼ3 times with 3 replicates per experiment. In some studies, due to differing potencies of different batches of TNF␣, fold-change in the number of adhered monocytes during flow relative to TNF␣ in each experiment were calculated and then averaged. Significance was assessed by either paired t test or by one-way ANOVA with post hoc analysis using Tukey test as indicated. Significance was set at a value of p Ͻ 0.05. Statistical analyses were performed using GraphPad software.

TNF␣ Stimulates Expression of High Mannose and/or Hybrid N-Glycans at Endothelial Cell Junctions-
The hypothesis that inflammatory stimuli alter the expression of glycans on the endothelial cell surface was tested by administration of TNF␣ to HUVEC and monitoring changes in glycoforms using a panel of fluorescently tagged lectins. The lectins used and their specificities for specific carbohydrate epitopes/linkages are described in Table 1. Fig. 1 shows representative fluorescence micrographs and Fig. 1C their quantitation and demonstrates that TNF␣ increased binding of ConA, DSL, and LCA but not jacalin, VVL, SNA lectin, or UEA1. Specificity of lectin binding to N-glycans, and to high mannose specifically, was indicated by the attenuation of TNF␣-dependent effects by addition of tunicamycin (5 M), an inhibitor of the rate-limiting step in N-glycosylation (not shown) or inclusion of ␣-methylmannoside during the staining procedure (Fig. 1B). Together, these data indicate increased expression of high mannose and/or hybrid N-glycans in response to TNF␣, but not complex N-glycans nor O-glycans. Fig. 1 suggests that increased N-glycans are localized at the plasma membrane and endothelial junctions. This was confirmed by co-localization of ConA, DSL, and LCA binding with the junctional protein occludin ( Fig. 2A) and for ConA and LCA (not shown) by confocal microscopy (Fig. 2B).
Endothelial Expression of High Mannose/Hybrid N-Glycans Modulate Monocyte-Endothelial Interactions-To test if increased high mannose/hybrid N-glycans contribute to TNF␣-dependent leukocyte rolling and adhesion to endothelial cells, a competition experiment was performed in which dynamic flow-dependent THP-1 monocyte adhesion to TNF␣activated HUVEC was evaluated in the absence and presence of increasing concentrations of ␣-methylmannose or ␣-methyl-glucose. The latter was included as an osmotic and negative control because it will not compete with mannose residues expressed on the endothelial cell surface. Fig. 3 shows that THP-1 adhesion during flow was not affected by ␣-methylglucose, but were significantly blunted when ␣-methylmannose (20 and 200 mM) was included in flow media. Inhibition was not complete, reaching maximal levels of ϳ60%, and neither ␣-methylmannose nor ␣-methylglucose affected THP-1 adhesion to TNF␣-stimulated HUVEC evaluated under static conditions (Fig. 3B).
Rosiglitazone Inhibits Monocyte-Endothelial Interactions during Flow-Our previous studies demonstrated that exposure of HUVEC to the synthetic PPAR␥ ligand rosiglitazone (2 M, 16 h) had no effect on TNF␣-dependent adhesion of THP-1 monocytes under static conditions. However, under the same experimental conditions, rosiglitazone did inhibit monocyte adhesion when assessed in the presence of flow (20). Fig. 4 extends these data to show that rosiglitazone inhibits THP-1 adhesion in a dose-dependent manner (Fig. 4A) and occurs at all flow rates tested (Fig. 4B). Fig. 4, C and D, shows that TNF␣ increased expression of E-selectin and ICAM-1, two candidate adhesion molecules important in mediating rolling and adhe-   sion, and which are also N-glycosylated (22)(23)(24). Whereas this increase was attenuated by BAY-117082, an antagonist of the NFB pathway and used as a positive control for inhibition, rosiglitazone had no effect, a result similar to our previous study with other PPAR␥ ligands (19). Finally, rosiglitazone did not affect TNF␣-dependent up-regulation of ICAM-1 or VCAM-1 mRNA determined by RT-PCR (Table 2), underscoring the lack of effect of rosiglitazone on adhesion molecule expression.

Effects of Mannose and Rosiglitazone on Primary Human Monocyte Adhesion during Flow-Differences between THP-1 cells (human leukemia cell line) and primary human monocytes have been documented.
To test if monocyte cell transformation endows sensitivity to mannose and the rosiglitazone effects reported above, primary human monocytes were freshly isolated and flow-dependent adhesion to TNF␣-activated HUVEC Ϯ rosiglitazone or in the presence of ␣-methylmannose (as described above) was determined. Fig. 5 shows that competition assays with ␣-methylmannose in the flow media or pre-treatment of HUVEC with rosiglitazone inhibited monocyte adhesion during flow in a similar manner to that observed with THP-1 cells.
PPAR␥ Ligands Inhibit TNF␣-dependent Expression of Endothelial N-Glycans-We hypothesized that one mechanism by which rosiglitazone may attenuate monocyte-endothelial interactions only during flow and in the absence of adhesion molecule expression changes, is to regulate adhesion molecule N-glycosylation. Fig. 6A shows that rosiglitazone inhibits ConA binding to TNF␣-treated HUVEC in a dose-dependent manner that parallels inhibitory effects on THP-1 adhesion during flow. These effects of rosiglitazone were reversed by co-addition of the PPAR␥ antagonist GW9662 (Fig. 6B). The PPAR␣ agonist benzofibrate had no effect on TNF␣-dependent increased ConA binding (not shown). Furthermore, various structurally distinct PPAR␥ ligands, but not vehicle controls, all inhibited TNF␣-dependent increases in ConA binding (Fig. 6C). These data reveal a novel molecular target for anti-inflammatory effects of PPAR␥ ligands directed toward endothelial N-glycoforms.
Rosiglitazone Reverses TNF␣-dependent Down-regulation of ␣-Mannosidase Activity-To determine potential targets for (i) how TNF␣ modulates protein N-glycosylation and (ii) how PPAR␥ activation reverses this, a targeted gene array for human glycosylation genes was performed. Fig. 7A shows a heat map indicating relative expression changes of 24 genes involved in N-glycan processing in control, rosiglitazone, TNF␣, and  TNF␣ ϩ rosiglitazone-treated HUVEC. Of the genes in Fig. 7A, only 4 showed Ն 2-fold change after TNF␣ and significant reversal of TNF␣ effects by rosiglitazone; these 4 proteins were MAN1A2, MAN1C1, B4GALT1, and ST6GAL1. Fig. 7B shows that TNF␣ decreased expression of MAN1A2 and MAN1C1, and increased expression of B4GALT1 and ST6GAL1, with rosiglitazone significantly reversing these effects. Fig. 7C shows that changes in ␣-mannosidase gene expression were mirrored by concomitant changes in ␣-mannosidase enzyme activity with TNF␣ decreasing activity compared with control, a decrease that was prevented by pretreatment with rosiglitazone (Fig. 7C).

DISCUSSION
The anti-inflammatory effects of PPAR␥ activation in endothelial cells can occur via several mechanisms prominent of which is inhibition of proinflammatory cytokine-dependent up-regulation of adhesion molecule expression (25,26). Our previous studies (19,20), which were confirmed herein, have shown that activation of PPAR␥ can also attenuate TNF␣-dependent THP-1 rolling and adhesion to endothelial cells without altering adhesion molecule expression. In this study, evidence is provided for a novel PPAR␥-dependent anti-inflammatory mechanism that involves regulation of endothelial N-glycosylation.
Protein N-glycosylation is a multiple step process that ultimately results in 3 types of N-glycoforms: high mannose, hybrid, or complex-type (27). Generally, N-glycosylated proteins are targeted for secretion or expression on the cell surface. Despite the knowledge that adhesion molecules are N-glycosylated (6), relatively little is known about the regulation or functional effects of N-glycosylation in immune cell-endothelial interactions. However, a role in the TNF␣-dependent effects can be postulated based on findings that this proinflammatory cytokine modulates the pattern of N-glycosylation in synoviocytes (28), mediates interconversion between high mannose and hybrid N-glycans in epithelial cells (29), and affects expression of genes encoding enzymes responsible for protein N-glycosylation in endothelial cells (29,30). Similarly, tumor-conditioned media-dependent alteration of endothelial N-glycan composition has been proposed to be important in tumor extravasation (31). Several studies have also demonstrated the functional effects of altered endothelial N-glycosylation. For example, aberrant N-glycosylation of E-cadherin is associated with carcinogenesis secondary to altered cell-cell adhesion and

Control
Rosiglitazone TNF␣  NOVEMBER 4, 2011 • VOLUME 286 • NUMBER 44 communication (32). With respect to leukocyte interactions specifically, increased expression of carboxylated N-glycans (33) or N-linked high mannose sugars (10, 11) on endothelial cells have been implicated in mediating neutrophil adhesion under static conditions. Furthermore, inhibition of N-glycan synthesis decreases IL-1-mediated lymphocyte binding to endothelial cells (34) and high endothelial venular expression of N-glycans has been shown to be critical to support L-selectinmediated lymphocyte trafficking (9). Interestingly, in the latter case, evidence that alteration of N-glycan composition independent of the adhesion molecule expression, was important in lymphocyte homing was provided. Our data support and develop these concepts by demonstrating that TNF␣-dependent modulation of N-glycosylation is regulated by pathways distinct to those that modulate expression of adhesion molecules. Specifically, lectin staining studies showed that TNF␣ treatment of endothelial cells increases high mannose/hybrid N-glycan expression, which was inhibited by PPAR␥ ligands. Increased high mannose/hybrid N-glycan expression was observed at endothelial cell junctions, which are also sites where adhesive interactions with leukocytes occur (35)(36)(37)(38). Moreover, TNF␣ also increased expression of ICAM-1, VCAM-1, and E-selectin, which are important mediators of monocyte rolling and adhesion. However, the increased expression of these adhesion molecules was not affected by PPAR␥ ligands, yet THP-1 adhesion was decreased, suggesting increased adhesion molecule expression alone is insufficient to mediate monocyte adhesion. Finally, the observation that THP-1 adhesion was attenuated by coincubation of ␣-methyl-   (n ϭ 3). #, p Ͻ 0.05 relative to control and *, p Ͻ 0.05 relative TNF␣ ϩ DMSO by one-way ANOVA with Tukeys post hoc test. Panel B, surface binding of ConA was determined in HUVEC after treatment with rosiglitazone (2 M Ϯ GW 9662 (5 M) followed by TNF␣ (10 ng/ml, 4 h). PPAR␥ agonist/ antagonists were administered for 20 h prior to TNF␣ addition. FITC-ConA binding was determined by increases in fluorescence using a plate reader after live cell labeling. Data are mean Ϯ S.E., n ϭ 8. *, p ϭ Ͻ0.01 relative to control; #, p ϭ Ͻ0.01 relative to TNF␣ by one-way ANOVA with Tukeys post hoc test. Panel C, HUVEC were exposed control, ethanol (EtOH, 0.5%, v/v), or PPAR␥ ligands, ciglitazone (2 M), troglitazone (2 M), 15-deoxy-PGJ 2 (5 M), or LNO 2 (2 M) (50) for 16 h and TNF␣ (10 ng/ml, 4 h). ConA binding was then determined by lectin fluorescence and plotted as a fold-change relative to respective control. Data show mean Ϯ S.E. *, p Ͻ 0.01 relative to respective no TNF␣ treatment group by Student's t test.

PPAR␥ Inhibits Endothelial N-Glycans
mannose, but not ␣-methylglucose, suggests a model wherein TNF␣ stimulates the adhesion molecule and regulates their N-glycosylation, by independent pathways. In this model, the post-translational modification by the N-glycosylation pathway is a novel target for PPAR␥ ligands. It is also important to note that because N-glycosylation is essential for protein trafficking, targeting this modification might result in inhibition of leukocyte adhesion simply by preventing appropriate movement to the plasma membrane. However, rosiglitazone did not alter surface expression of ICAM-1, VCAM-1, and E-selectin. Taken together with ␣-methylmannose-dependent inhibition of THP-1 adhesion (Fig. 3 and Refs. 10 and 11), we propose that regulation of the mannose composition of surface adhesion molecules is a novel anti-inflammatory mechanism for PPAR␥ ligands.
This model is also consistent with the fact that adhesion molecules are the scaffolds for the actual ligands (namely glycosylated and sulfated epitopes (6)) that mediate adhesive interactions with cognate receptors. It has also been suggested that under basal conditions not all expressed adhesion molecules are functional due to incorrect glycosylation (7). These concepts have led to the suggestion that the glycosylation process may be regulated by distinct pathways to those that regulate adhesion molecule expression (12), which is supported by data reported herein.
Little is known on how TNF␣ and PPAR␥ activation modulate endothelial glycosylation. Previous gene array studies (29) suggest that the myriad of glycosyl and mannosyltransferases that act in concert to control the pattern of protein N-glycosylation in the endoplasmic reticulum and Golgi complex are potential targets. This was confirmed by targeted N-glycan processing gene array studies that identified ␣-mannosidases MANA2 and MANC1, and B4GALT1 and ST6GAl1 as proteins whose expression was modulated by TNF␣ and reversed by rosiglitazone. MAN1A2 and MAN1C1 are ␣1,2-mannosidases that catalyze the earliest steps of mannose removal required for the conversion of high mannose to hybrid and subsequently complex N-glycans. B4GALT1 (facilitates galactose addition) and ST6GAL1 (adds sialic acid in ␣2,6-conformation to galactose residues) catalyze latter steps in N-glycan maturation. It is important to note that the sequential nature of the N-glycosylation process ensure that the end pattern of N-glycosylation is regulated by enzymes catalyzing the earlier steps. For example, Fig. 7B shows that ST6GAL1, which catalyzes the terminal addition of ␣1,2-sialic acid onto galactose residues on N-glycan structures, increases in response to TNF␣. However, binding of S. nigra lectin, a lectin specific for ␣2,6-sialic acid, did not increase after TNF␣ treatment (see Fig. 1). This is likely explained by the fact that expression of the upstream mannosidases MAN1A2 and MAN1C1 decreased (a result consistent with increased ConA binding (Fig. 1)), which is predicted to prevent N-glycan maturation beyond high mannose types. Importantly, PPAR␥ activation reversed TNF␣-dependent ␣-mannosidase down-regulation and gene expression changes translated into concomitant changes in ␣-mannosidase activity (Fig. 7C). Interestingly, four distinct ␣1,2-mannosidases exist, and despite the redundancy in their activities, down-regulation of two of these still significantly (ϳ20%) decreased total cellular ␣1,2-mannosidase enzymatic activity.
We have not identified the specific protein(s) whose N-glycosylation status is affected by TNF␣ and PPAR␥ activation. One potential candidate is ICAM-1, which can mediate both rolling and adhesive phases of leukocyte adhesion to endothelial cells (39). Appropriate ICAM-1 N-glycosylation ensures correct protein folding and trafficking to the cell surface. Also the pattern of N-glycosylation on the third extracellular IgGlike domain of ICAM-1 is key for binding the cognate receptor, CD11b (Mac-1) (22,23). Specifically, inhibiting the processing of high mannose to complex N-glycans increased CD11b binding to ICAM-1 (22). The aforementioned study concluded that by decreasing the branching and hence size of N-glycans (by preventing complex N-glycan formation), steric effects were minimized leading to enhanced CD11b binding. Previous data FIGURE 7. Effects of rosiglitazone on TNF␣-induced changes in N-glycan processing enzyme expression. HUVECs were untreated (control) or treated with TNF␣ (10 ng/ml) Ϯ rosiglitazone (2 M, 20 h) alone or in combination with TNF␣ (last 4 h). RNA was collected, cDNA was synthesized, and glycosylation gene expression was analyzed using the SAbiosciences TM human glycosylation PCR array. A, heat map of select N-glycosylation specific genes; B, relative (to control) changes in expression of mannosyl-oligosaccharide ␣1,2mannosidase 1B (MAN1A2), mannosidase, ␣, class 1C, member 1 (MAN1C1), ␤1,4-galactosyltransferase 1 (B4GALT1), ␤-galactoside ␣2,6-sialyltransferase 1 (ST6GAL1). Fold-changes are standardized to ␤ 2 -microglobulin. Data are mean Ϯ S.E. from 3 experiments per condition. *, p Ͻ 0.05; #, p Ͻ 0.01 by t test. C, relative ␣-mannosidase activities (normalized to protein). Data show mean Ϯ S.E. (n ϭ 4 -6). *, p Ͻ 0.05 relative to control; #, p Ͻ 0.01 relative to TNF␣ by one-way ANOVA with Tukeys post hoc test.
(10) and data presented herein using a ␣-methylmannosebased competition offer an alternative explanation whereby high mannose/hybrid N-glycans are directly engaged in binding of cognate receptors. Consistent with this, monocyte integrins (e.g. MAC-1) have been shown to possess lectin sites were mannose binding can occur (40). Unlike previous studies, however, our data only revealed a role for high mannose/hybrid N-glycans when THP-1 adhesion was assessed during flow. The basis of this difference is not clear and we note that competition experiments showed maximal inhibition of ϳ60% suggesting that high mannose N-glycans are not the only mediators of leukocyte recruitment. This is consistent with functional redundancy among multiple binding sites within a given endothelial adhesion molecule, and between different adhesion molecules themselves and we note that further studies are required to determine the proteins whose N-glycosylation status is regulated during inflammation.
Emerging data are highlighting the importance of the glycocalyx as a key site for regulating the inflammatory cascade with the concept being that proinflammatory stimuli (e.g. TNF␣, hyperglycemia or oxidized low-density lipoprotein) induce shedding of glycosaminoglycans thereby decreasing the width and size of the endothelial glycocalyx (13,(41)(42)(43)(44)(45)(46)(47). This in turn allows greater accessibility of circulating macromolecules to underlying glycoproteins (e.g. adhesion molecules) that present their epitopes to which circulating leukocytes roll and adhere. The model presented here suggests that in concert with decreased glycocalyx size, TNF␣ also modulates the pattern of N-glycosylation at endothelial junctions, which in turn mediates higher affinity interactions with circulating monocytes.
In summary, evidence is provided that TNF␣ increases high mannose/hybrid N-glycans expression at endothelial junctions and that these sugars are important in controlling monocyte trafficking by mediating rolling and adhesion. This model is consistent with a recent hypothesis that forward a key role for core N-glycan structures (i.e. mannose) in providing signals to the innate immune system for recognizing cells under inflammatory stress (48,49). We extend this model further by showing that endothelial PPAR␥ activation may be an important regulator of this process, which also provides a novel anti-inflammatory mechanism for activation of these nuclear receptors.